floo-OX-uh-teen 
Unlabeled Use:
Contraindicated in:
Use Cautiously in:
CV: QT interval prolongation, chest pain, palpitations, TORSADES DE POINTES.
Derm: ↑ sweating, pruritus, erythema nodosum, flushing, rash.
EENT: mydriasis, stuffy nose, visual disturbances.
Endo: SIADH, dysmenorrhea, hot flush.
F and E: hyponatremia.
GI: diarrhea, abdominal pain, abnormal taste, anorexia, constipation, dry mouth, dyspepsia, nausea, vomiting, weight loss.
GU: ↓ libido, delayed/absent orgasm, ejaculatory delay/failure, erectile dysfunction, urinary frequency.
Hemat: BLEEDING.
MS: arthralgia, back pain, myalgia.
Neuro: anxiety, drowsiness, headache, insomnia, nervousness, tremor, abnormal dreams, dizziness, fatigue, hypomania, mania, NEUROLEPTIC MALIGNANT SYNDROME, SEIZURES, SUICIDAL THOUGHTS, weakness.
Resp: cough.
Misc: fever, flu-like syndrome, hypersensitivity reactions, SEROTONIN SYNDROME.
Drug-Drug:
Drug-Natural Products:
(Generic available)
PROzac, Sarafem
Therapeutic Classification: antidepressants
Pharmacologic Classification: selective serotonin reuptake inhibitors ssris
Absorption: Well absorbed after oral administration.
Distribution: Crosses the blood-brain barrier.
Protein Binding: 94.5%.
Metabolism/Excretion: Converted by the liver to norfluoxetine (primarily by the CYP2D6 isoenzyme), another antidepressant compound; the CYP2D6 enzyme system exhibits genetic polymorphism (7% of population may be poor metabolizers and may have significantly ↑ fluoxetine concentrations and an ↑ risk of adverse effects). Fluoxetine and norfluoxetine are mostly metabolized by the liver; 12% excreted by kidneys as unchanged fluoxetine, 7% as unchanged norfluoxetine.
Half-life: 1–3 days (norfluoxetine 5–7 days).
NDC Code*
